Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

514
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
514
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K
Fats as Energy Storage Molecules01:06

Fats as Energy Storage Molecules

26.7K
Triglycerides are a form of long-term energy storage molecules. They are made of glycerol and three fatty acids. To obtain energy from fat, triglycerides must first be broken down by hydrolysis into their two principal components, fatty acids and glycerol. This process, called lipolysis, takes place in the cytoplasm. The resulting fatty acids are oxidized by β-oxidation into acetyl-CoA, which is used by the Krebs cycle. The glycerol that is released from triglycerides after lipolysis...
26.7K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

4.6K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

277
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
277

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular event rate modifies response to pharmacologic LDL-C lowering in primary prevention: implications of a systematic review and meta-analysis for clinical practice.

American journal of preventive cardiology·2026
Same author

Obicetrapib safety analysis: Pooled phase 3 clinical trial experience.

American journal of preventive cardiology·2026
Same author

Obesity, metabolic health status, and adverse outcomes in men and women.

American journal of preventive cardiology·2026
Same author

Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI study.

BMJ open·2026
Same author

Cholesterol-lowering therapy from childhood/adolescence and long-term outcomes in familial hypercholesterolaemia: the SAFEHEART study.

European heart journal·2026
Same author

Obicetrapib and renal function: A welcome signal, but not yet a kidney story.

American journal of preventive cardiology·2026

Related Experiment Video

Updated: Dec 28, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K

Triglycerides and residual risk.

Antonio J Vallejo-Vaz1, Pablo Corral2, Laura Schreier3

  • 1Imperial Centre for Cardiovascular Disease Prevention (ICCP), Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK.

Current Opinion in Endocrinology, Diabetes, and Obesity
|February 20, 2020
PubMed
Summary

Higher triglycerides are linked to increased cardiovascular risk. High-dose icosapent-ethyl (EPA) may benefit high-risk patients with hypertriglyceridemia, potentially through non-lipid pathways.

More Related Videos

Author Spotlight: Quantification of Complex Lipidomic Samples Using Stable Isotope Labeling
07:12

Author Spotlight: Quantification of Complex Lipidomic Samples Using Stable Isotope Labeling

Published on: August 23, 2024

1.8K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.3K

Related Experiment Videos

Last Updated: Dec 28, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K
Author Spotlight: Quantification of Complex Lipidomic Samples Using Stable Isotope Labeling
07:12

Author Spotlight: Quantification of Complex Lipidomic Samples Using Stable Isotope Labeling

Published on: August 23, 2024

1.8K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.3K

Area of Science:

  • Cardiology
  • Metabolic Syndrome
  • Pharmacology

Background:

  • Elevated triglycerides are consistently associated with increased cardiovascular risk (CVRisk).
  • Genetic studies confirm an independent relationship between triglyceride metabolism and CVRisk.
  • Residual CVRisk remains a significant concern despite statin therapy.

Purpose of the Study:

  • To review current evidence on the role of triglycerides in residual cardiovascular risk.
  • To evaluate genetic, observational, and interventional data linking triglycerides to CVRisk.
  • To assess the efficacy of various therapeutic interventions for managing hypertriglyceridemia and CVRisk.

Main Methods:

  • Review of large population-based and secondary prevention studies.
  • Analysis of genetic studies, including Mendelian randomization.
  • Evaluation of data from major cardiovascular outcome trials (e.g., statin, PCSK9 inhibition, n-3 fatty acids).

Main Results:

  • Higher triglycerides are a marker for increased CVRisk and identify patients who may benefit from intensified therapy.
  • Genetic evidence supports a causal link between triglyceride-rich lipoproteins (TRL) and cardiovascular disease.
  • High-dose icosapent-ethyl (purified EPA) demonstrated significant cardiovascular event reductions in hypertriglyceridemic patients, possibly via non-lipid mechanisms.

Conclusions:

  • Triglycerides are a significant marker of residual cardiovascular risk.
  • Genetic data support a causal role for TRL in cardiovascular disease.
  • High-dose icosapent-ethyl shows promise for reducing cardiovascular events in high-risk hypertriglyceridemic individuals.